Victory Capital Management Inc. Acquires 6,519 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Victory Capital Management Inc. boosted its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 101,759 shares of the company’s stock after purchasing an additional 6,519 shares during the quarter. Victory Capital Management Inc.’s holdings in iTeos Therapeutics were worth $782,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. US Bancorp DE raised its holdings in iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company’s stock valued at $130,000 after acquiring an additional 4,843 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in iTeos Therapeutics in the 4th quarter valued at approximately $142,000. Peapod Lane Capital LLC acquired a new position in iTeos Therapeutics in the 4th quarter valued at approximately $836,000. Empowered Funds LLC raised its holdings in iTeos Therapeutics by 5.0% in the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock valued at $530,000 after acquiring an additional 3,305 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after acquiring an additional 1,508 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. JPMorgan Chase & Co. cut their price target on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, Wells Fargo & Company dropped their target price on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Trading Down 1.0 %

Shares of ITOS opened at $6.89 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $6.67 and a 1 year high of $18.75. The stock has a 50 day simple moving average of $7.41 and a 200-day simple moving average of $8.84. The stock has a market cap of $263.16 million, a PE ratio of -2.19 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. On average, sell-side analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.